Using plants as bioreactors to produce proteins for therapeutics
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
List view / Grid view
European Pharmaceutical Review explores how plants can be used for large-scale, glycosylated protein bioproduction for the pharma industry.
Dr Finn Bauer discusses how Merck KGaA and its SAFC® portfolio brand is addressing drug formulator challenges.
In the light of recent media coverage about product recalls – particularly resulting from the detection and presence of NDMA – this article outlines ways to avoid the wide-ranging negative impacts on patients, pharmacies, manufacturers, pharmaceutical companies and health authorities and offers ways to mitigate the risk of future recalls.
In this in-depth focus are articles discussing how to optimise production by using the correct tablet tooling and why logistics can be affected by developments in the pharmaceutical industry.
Scientists have divised a way to manufacture protein drugs using lettuce leaves, which has presented a potential drug for pulmonary arterial hypertension.
European Pharmaceutical Review attended a JPAG event, exploring the plethora of uses for in silico techniques in the pharmaceutical industry.
Within this issue are articles which investigate polyelectrolyte multilayers as drug carriers, discuss how developments in pharma impact logistics and examine how the industry can regulate heavy metals in medicinal cannabis. Other features include how to use the correct tablet tooling and trends for the CDMO sector this year.
This whitepaper from NSF looks at the key causes of drug shortages and what we can do to stop them.
A collaboration between the NIBRT and Avantor aims to address issues faced in downstream bioprocessing during buffer preparation for mAbs.
A report suggests that instead of taxing medical device imports, the Indian government should offer tax rebates to multinational companies if they partner with domestic device manufacturers.
The government in the UK has told pharmaceutical businesses to examine the risk that coronavirus poses to the supply chain and retain any stockpiles from Brexit to mitigate shortages.
EFPIA, Medicines for Europe and AESGP have called for a Mutual Recognition Agreement on good manufacturing practice in regards to the future relationship between the UK and the EU.
A report has outlined the opportunities and challenges for the pharmaceutical industry in south-east Asia, including implementing a track and trace system as well as generics potential.
A study showed that bone stem cells rearrange degrading microporous annealed particle (MAP) hydrogels, promoting their growth.
Out of specification results from stability studies have led Glenmark Pharmaceuticals to recall batches of their iohexol solution for injection in the UK.